Originally developed as chemosensitizers and radiosensitizers due to CHK1's essential role maintaining genome integrity via WEE1 activation, CHK1 inhibitors also have potential as single agents to exploit cancer-cell-specific vulnerabilities (McNeely et al., 2014, Rundle et al., 2017). Here, WEE1 is linked to cancer.